TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7493828

Group type: EXPERIMENTAL
Intervention: Conformal brachytherapy (CB) with HDR boost implants (5.5 Gy, 6 Gy, 6.5 Gy)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Interactive online planning system for HDR treatment
Number of subjects: 59
Study: 1748134

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Adverse event monitoring system
Number of subjects: 251
Study: 6127890

Group type: EXPERIMENTAL
Intervention: Prenalterol 20‐200 mg daily (slow‐release tablet preparation)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31563406

Group type: EXPERIMENTAL
Intervention: HIIT in a swimming pool
Number of subjects: 42

Group type: COMPARATOR
Intervention: MICT on dry land
Number of subjects: 42

Group type: COMPARATOR
Intervention: HIIT on dry land
Number of subjects: 42
Study: 27254743

Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU daily)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg daily)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU daily) + Calcium (1200 mg daily)
Number of subjects: 104
Study: 27603424

Group type: EXPERIMENTAL
Intervention: BCG monotherapy (Connaught 120 mg, 6 weekly instillations followed by 10 instillations)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Alternating therapy with mitomycin C (MMC 40 mg, 6 weekly instillations followed by 10 instillations of BCG)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: BCG monotherapy
Number of subjects: 321

Group type: COMPARATOR
Intervention: Alternating therapy with MMC and BCG
Number of subjects: 321
Study: 24478050

Group type: EXPERIMENTAL
Intervention: Whole-grain intake for 6 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no whole-grain intake for 6 weeks)
Number of subjects: 44
Study: 22186981

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 11140
Study: 20854115

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17209660

Group type: EXPERIMENTAL
Intervention: Abatacept (CTLA4Ig)
Number of subjects: 0
Study: 15214141

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (400 ml, 400 kcal) daily for six months
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (400 ml) daily for six months
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Patients with protein‐energy malnutrition
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Patients without protein‐energy malnutrition
Number of subjects: 53
Study: 12043862

Group type: EXPERIMENTAL
Intervention: Pumped Diodium‐Nd:YAG laser (5 Hz for 15 s)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pumped Diodium‐Nd:YAG laser (10 Hz for 15 s)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5.25% NaOCl
Number of subjects: 60
Study: 9619529

Group type: EXPERIMENTAL
Intervention: Intra-nasal buserelin (doses ranged from a single 25 microg dose to 100 microg every 4 h for 20 h)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intra-nasal buserelin
Number of subjects: 34
Study: 7655763

Group type: EXPERIMENTAL
Intervention: 12 g piracetam i.v. (250 ml infusion over 30 minutes)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 12 g piracetam p.o. (60 ml sirup)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2073165

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg OD
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6772199

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol (320 mg total)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metoprolol (400 mg total)
Number of subjects: 8
Study: 30488229

Group type: EXPERIMENTAL
Intervention: Self-affirmation group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-affirmation (control) group
Number of subjects: 48
Study: 28523589

Group type: EXPERIMENTAL
Intervention: Alternating acetaminophen and ibuprofen (acetaminophen 10 mg/kg per dose with shortest interval of 4 h and ibuprofen 10 mg/kg per dose with shortest interval of 6 h; n=158)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Acetaminophen monotherapy (10 mg/kg per dose with shortest interval of 4 h; n=158)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Ibuprofen monotherapy (10 mg/kg per dose with shortest interval of 6 h; n=158)
Number of subjects: 474
Study: 25945551

Group type: EXPERIMENTAL
Intervention: Continuous flow oxygen at 1 lpm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous flow oxygen at 2 lpm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous flow oxygen at 3 lpm
Number of subjects: 30
Study: 23789747

Group type: EXPERIMENTAL
Intervention: Postoperative PCA with tramadol (20 mg) and metoclopramide (1 mg) per bolus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Postoperative PCA with morphine (1 mg) per bolus
Number of subjects: 60
Study: 21298442

Group type: EXPERIMENTAL
Intervention: Upper step (US) transition to 90% estimated lactate threshold
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Full step (FS) transition to 90% estimated lactate threshold
Number of subjects: 7

Group type: COMPARATOR
Intervention: Lower step (LS) transition to 90% estimated lactate threshold
Number of subjects: 7
Study: 18586338

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 45852

Group type: COMPARATOR
Intervention: Aspirin alone (Control)
Number of subjects: 45852
Study: 17347471

Group type: EXPERIMENTAL
Intervention: Magnesium (n=383)
Number of subjects: 765

Group type: COMPARATOR
Intervention: Placebo (n=382)
Number of subjects: 765
Study: 14990013

Group type: EXPERIMENTAL
Intervention: Rabeprazole (10 mg twice daily) + Amoxicillin (1000 mg twice daily) + Clarithromycin (500 mg twice daily) for 1 week (RAC group)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Rabeprazole (10 mg twice daily) + Amoxicillin (1000 mg twice daily) + Metronidazole (400 mg twice daily) for 1 week (RAM group)
Number of subjects: 128
Study: 11178222

Group type: EXPERIMENTAL
Intervention: Heated humidifier (HH)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydrophobic heat-moisture exchanger (HME)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hygroscopic heat-moisture exchanger (HME)
Number of subjects: 10
Study: 9877365

Group type: EXPERIMENTAL
Intervention: Immunoglobulins extracted from immunized bovine colostrum (IIBC) 10 g daily for 4 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo preparation (10 g daily for 4 days)
Number of subjects: 80
Study: 7992594

Group type: EXPERIMENTAL
Intervention: Idarubicin on days 1, 3, 5 plus arabinoside cytosine 1‐7/10 plus etoposide 1‐5 (ICE7/10)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Daunorubicin on days 1‐3 plus Ara‐C 1‐7/10 with additional HD Ara‐C if insufficient cytoreduction (3+7+/‐HD)
Number of subjects: 56
Study: 2499160

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 707

Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 707
Study: 939850

Group type: EXPERIMENTAL
Intervention: Day treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 59
Study: 30770745

Group type: EXPERIMENTAL
Intervention: Stereotactic single-fraction radiosurgery (SRS) or stereotactic fractionated radiotherapy (SFRT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Optimal supportive care (SC)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of resection, post-operative SRS/SFRT and SRS/SFRT to intact lesions
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hypothetical protocol investigating radiotherapy utilization in the last 30 days of life
Number of subjects: 17
Study: 27617368

Group type: EXPERIMENTAL
Intervention: Respiratory-related clinician action
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Visiting physician with a respiratory issue
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Already prescribed a respiratory medication
Number of subjects: 994
Study: 24832954

Group type: EXPERIMENTAL
Intervention: Moms' Empowerment Program (10-session evidence-based intervention)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 120
Study: 23910581

Group type: EXPERIMENTAL
Intervention: Nesiritide therapy (0.006 μg kg(‐1) min(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21142788

Group type: EXPERIMENTAL
Intervention: MSCs coinfusion (3-5 × 10(5) cells/kg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: MSCs coinfusion
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 19695193

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 45
Study: 17412329

Group type: EXPERIMENTAL
Intervention: Soy protein supplement
Number of subjects: 15

Group type: COMPARATOR
Intervention: Isocaloric casein placebo
Number of subjects: 15
Study: 15118618

Group type: EXPERIMENTAL
Intervention: 20 microg ethinyl estradiol + 100 microg levonorgestrel followed by 7 pill-free days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 20 microg ethinyl estradiol + 150 microg desogestrel followed by 2 days of placebo then 10 microg ethinyl estradiol for 5 days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 28 days of 20 microg ethinyl estradiol + 150 microg desogestrel
Number of subjects: 54

Group type: COMPARATOR
Intervention: 7-day pill-free interval
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Overweight women (BMI > 25 kg/m²)
Number of subjects: 54
Study: 11310514

Group type: EXPERIMENTAL
Intervention: Rx medibottle
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral syringe
Number of subjects: 30
Study: 9141918

Group type: EXPERIMENTAL
Intervention: Left atrial administration of epinephrine at 100 ng.kg‐1.min‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Right atrial administration of epinephrine at 100 ng.kg‐1.min‐1
Number of subjects: 10
Study: 7894222

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) and Unfractionated heparin
Number of subjects: 230
Study: 3690032

Group type: EXPERIMENTAL
Intervention: 200 mg almitrine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 31462757

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 20
Study: 29376761

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg spray
Number of subjects: 505

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 505
Study: 26928760

Group type: EXPERIMENTAL
Intervention: Before CPB
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: After CPB
Number of subjects: 101
Study: 25911115

Group type: EXPERIMENTAL
Intervention: Culprit lesions with plaque rupture
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Culprit lesions without plaque rupture
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Culprit lesions with calcified nodules
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: OCT at 6 months for lesions with plaque rupture
Number of subjects: 80

Group type: COMPARATOR
Intervention: OCT at 6 months for lesions without plaque rupture
Number of subjects: 80
Study: 22981306

Group type: EXPERIMENTAL
Intervention: SMS-RUTFh (soy/maize/sorghum ready-to-use therapeutic food)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (P-RUTF; peanut-butter/milk-powder paste)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: SMS-RUTFh
Number of subjects: 41
Study: 20536334

Group type: EXPERIMENTAL
Intervention: High-intensity stress group (n = 13)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No-stress control group (n = 14)
Number of subjects: 27
Study: 18720323

Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia (N = 4)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Usual care (N = 5)
Number of subjects: 9
Study: 16796150

Group type: EXPERIMENTAL
Intervention: Fish-oil (4 g/day)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Soy-oil (4 g/day)
Number of subjects: 400
Study: 12605201

Group type: EXPERIMENTAL
Intervention: Continuous 12-lead ECG monitoring
Number of subjects: 119

Group type: COMPARATOR
Intervention: Chest pain unit protocol
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: ST-segment changes (greater than 100 microV in 2 or more contiguous leads or greater than 200 microV in 1 lead)
Number of subjects: 119
Study: 10799796

Group type: EXPERIMENTAL
Intervention: Postoperative pain medications before educational program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative pain medications after educational program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost of acute postoperative pain medication
Number of subjects: 0
Study: 8638023

Group type: EXPERIMENTAL
Intervention: EP-guided antiarrhythmic drug therapy (propafenone, flecainide, disopyramide, sotalol, amiodarone)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Empiric amiodarone
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Amiodarone (in patients with implantable cardioverter/defibrillator)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Empiric metoprolol
Number of subjects: 398
Study: 1597023

Group type: EXPERIMENTAL
Intervention: E5 2.5 mg/kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: E5 7.5 mg/kg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: E5
Number of subjects: 39
Study: 3904810

Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30314856

Group type: EXPERIMENTAL
Intervention: ACTI-BREAK intervention (3×5min active breaks incorporated into classroom routine daily)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Usual teaching practice (control group)
Number of subjects: 374
Study: 29305792

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine hydrochloride (30 cm3, 0.25%)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no bupivacaine hydrochloride)
Number of subjects: 120
Study: 27208511

Group type: EXPERIMENTAL
Intervention: Assertive Outreach (AO) program
Number of subjects: 295

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 295
Study: 24697278

Group type: EXPERIMENTAL
Intervention: Controlled-release cilostazol formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pletal (twice-daily immediate-release formulation)
Number of subjects: 0
Study: 22543813

Group type: EXPERIMENTAL
Intervention: Active experimental group (30-min exercise session)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Active control group (monitored physical activity)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Non-active experimental group (30-min exercise session)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Non-active control group (monitored physical activity)
Number of subjects: 4
Study: 20400005

Group type: EXPERIMENTAL
Intervention: Propofol 1.3 mg/kg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Propofol 1.6 mg/kg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Propofol 2.3 mg/kg
Number of subjects: 88
Study: 17122976

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 192

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 192
Study: 16377698

Group type: EXPERIMENTAL
Intervention: BAL8557 (100 mg of BAL4815)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BAL8557 (200 mg of BAL4815)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BAL8557 (400 mg of BAL4815)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BAL8557 (50 mg of BAL4815)
Number of subjects: 48
Study: 14645770

Group type: EXPERIMENTAL
Intervention: Relapse prevention intervention
Number of subjects: 386

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 386
Study: 10808172

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg with loratadine 10 mg
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study: 8673937

Group type: EXPERIMENTAL
Intervention: Ketorolac oral 10 mg at six hour intervals for 24 hours
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ketorolac injectable 10 mg at the height/depth of the buccal vestibule of the tooth to be treated
Number of subjects: 3

Group type: COMPARATOR
Intervention: No assigned medication (control group)
Number of subjects: 3
Study: 1633067

Group type: EXPERIMENTAL
Intervention: Frusemide 60 mg as two oral controlled release (CR) formulations
Number of subjects: 26

Group type: COMPARATOR
Intervention: Plain tablets of Frusemide 60 mg
Number of subjects: 26
Study: 6094278

Group type: EXPERIMENTAL
Intervention: Ketoconazole alone for 4 months (group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketoconazole in combination with chemical nail avulsion (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study: 31250992

Group type: EXPERIMENTAL
Intervention: RPh201 (5 mg, 10 mg, 20 mg) in SAD stage
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: RPh201 (5 mg, 10 mg, 20 mg) in MAD stage
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo in SAD stage
Number of subjects: 39
Study: 31271330

Group type: EXPERIMENTAL
Intervention: Uncemented joint replacement (Elektra)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trapeziectomy (with ligament reconstruction and tendon interposition, LRTI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Joint replacement (Elektra)
Number of subjects: 40
Study: 28923692

Group type: EXPERIMENTAL
Intervention: BioFreedom DCS
Number of subjects: 72
Study: 26487907

Group type: EXPERIMENTAL
Intervention: Cord blood 25-hydroxyvitamin D concentration
Number of subjects: 270
Study: 23508198

Group type: EXPERIMENTAL
Intervention: Instruction aimed at improving knee abduction during jump landings
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Home-based training following initial instruction
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham training (Control)
Number of subjects: 26
Study: 21821621

Group type: EXPERIMENTAL
Intervention: Combination of clinical items indicative of inflammatory back pain for diagnosing axial spondyloarthritis (SpA)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Combination of clinical items indicative of inflammatory back pain
Number of subjects: 950
Study: 19575689

Group type: EXPERIMENTAL
Intervention: Carrageenan-based microbicide
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 17450102

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) exposure during pregnancy
Number of subjects: 451

Group type: COMPARATOR
Intervention: Non-EFV exposure during pregnancy
Number of subjects: 451
Study: 14717627

Group type: EXPERIMENTAL
Intervention: Messages framed with emotional overtones matching the emotional state of the receiver (sadness)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Messages framed with emotional overtones matching the emotional state of the receiver (anger)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Emotion-induced expectancies attached to arguments in messages
Number of subjects: 2
Study: 11289194

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 600 mg
Number of subjects: 728

Group type: COMPARATOR
Intervention: Ofloxacin 400 mg
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg and 600 mg, Ofloxacin 400 mg
Number of subjects: 728
Study: 9263159

Group type: EXPERIMENTAL
Intervention: MOS Short Form 36 (SF‐36)
Number of subjects: 150
Study: 8174010

Group type: EXPERIMENTAL
Intervention: Brain MRI with normal neurological examination
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Brain MRI with abnormal neurological examination
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clinical neurological examination
Number of subjects: 16
Study: 3606238

Group type: EXPERIMENTAL
Intervention: Subcutaneous closed suction drainage
Number of subjects: 194

Group type: COMPARATOR
Intervention: Simple abdominal closure
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Wound infections
Number of subjects: 194

Group type: COMPARATOR
Intervention: Wound infections (subgroup analysis)
Number of subjects: 194
Study: 29044862

Group type: EXPERIMENTAL
Intervention: Vinorelbine plus cisplatin chemotherapy
Number of subjects: 40
Study: 27942103

Group type: EXPERIMENTAL
Intervention: Single-dose treatment (5 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Multiple doses (1.7 mg/kg three times a day)
Number of subjects: 80
Study: 25640401

Group type: EXPERIMENTAL
Intervention: 3h-AFL-PDT
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 2h-AFL-PDT
Number of subjects: 93

Group type: COMPARATOR
Intervention: 3h-MAL-PDT
Number of subjects: 93
Study: 23331997

Group type: EXPERIMENTAL
Intervention: Remote sensing method using GIS, Google Earth, Microsoft Excel, and handheld Garmin GPSmap 76CSx GPS units
Number of subjects: 537
Study: 20513659

Group type: EXPERIMENTAL
Intervention: High-scoring individuals on the Autism Spectrum Quotient
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low-scoring individuals on the Autism Spectrum Quotient
Number of subjects: 29
Study: 18308165

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 3560

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 3560